generátor elektrochirurgický voyant
applied medical resources corp. 22872 avenida empresa 92688 rancho santa margarita, ca spojené štáty americké -
nástroj elektrochirurgický voyant 5mm fusion
applied medical resources corp. 22872 avenida empresa 92688 rancho santa margarita, ca spojené štáty americké -
nástroj elektrochirurgický voyant fine fusion
applied medical resources corp. 22872 avenida empresa 92688 rancho santa margarita, ca spojené štáty americké -
nástroj elektrochirurgický voyant maryland fusion
applied medical resources corp. 22872 avenida empresa 92688 rancho santa margarita, ca spojené štáty americké -
nástroj elektrochirurgický voyant open fusion
applied medical resources corp. 22872 avenida empresa 92688 rancho santa margarita, ca spojené štáty americké -
ohrievač laparoskopickej optiky scope warmer
applied medical resources corp. 22872 avenida empresa 92688 rancho santa margarita, ca spojené štáty americké -
vrecko laparoskopické inzii
applied medical resources corp. 22872 avenida empresa 92688 rancho santa margarita, ca spojené štáty americké -
trokár laparoskopický kii
applied medical resources corp. 22872 avenida empresa 92688 rancho santa margarita, ca spojené štáty americké -
trokár laparoskopický kii fios
applied medical resources corp. 22872 avenida empresa 92688 rancho santa margarita, ca spojené štáty americké -
lonsurf
les laboratoires servier - trifluridine, tipiracil hydrochlorid - kolorektálne novotvary - antineoplastické činidlá - colorectal cancerlonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (crc) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and/or anti-egfr agents. lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti egfr agentsgastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.